Olivier Jean Bohuon
Plus aucun poste en cours
Fortune : 65 491 $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Stéphane Thiroloix | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 ans |
Catheryn O'Rourke | F | 52 | 11 ans | |
Cyrille Yann Nicolas Petit | M | 54 | 12 ans | |
Hubert Allen | M | 58 | 18 ans | |
Shannon Eisenhardt | M | - | 1 ans | |
Helen Barraclough | F | 45 | 11 ans | |
David Darroch | M | 61 | 2 ans | |
Masami Iijima | M | 73 | 3 ans | |
Edmund Harrigan | M | 71 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 3 ans |
Miki Tsusaka | F | 61 | 1 ans | |
Kimberly Reed | F | 53 | 2 ans | |
Susan O’Reilly | F | - | 5 ans | |
Bradley Cannon | M | 56 | 12 ans | |
Karin Hoeing | F | - | 4 ans | |
Marc E. Owen | M | 65 | 7 ans | |
Dame Dowling | M | 71 | 6 ans | |
Habib Ramdani | M | 48 | 8 ans | |
Pam Cheng | F | 53 | 4 ans | |
Angela Risley | F | 66 | 7 ans | |
Robert Alpern | M | 73 | 16 ans | |
Hugues le Bret | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 5 ans |
Jesper Brandgaard | M | 60 |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | 3 ans |
Charlotte Schofield | F | - | 2 ans | |
John Maraganore | M | 60 | 2 ans | |
Jun Ueki | M | - | 5 ans | |
Filippo Catalano | M | - | 3 ans | |
John M. Capek | M | 62 | 18 ans | |
Rakesh Narayana | M | 33 | 2 ans | |
John Ryan | M | - | 5 ans | |
Marybeth Hays | F | 55 | - | |
James Dinniss | M | - | 5 ans | |
Anthony Grannell | M | - | 5 ans | |
Paul Keogh | M | - | 5 ans | |
Anthony Denis Ahern | M | - | 5 ans | |
Tamara Ingram | F | 63 | 1 ans | |
Charles Reynolds | M | - | 13 ans | |
Jane M. Birgitta Stymne Göransson | F | 67 |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | 5 ans |
Rama Donepudi | M | - | 3 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Nicandro Durante | M | 67 | 10 ans | |
David J. Illingworth | M | 70 | 9 ans | |
Richard Gonzalez | M | 70 | 33 ans | |
Jeffrey Leiden | M | 68 | 6 ans | |
Gitte Pugholm Aabo | F | 57 |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | 27 ans |
Roland Diggelmann | M | 57 | 4 ans | |
Masato Iwasaki | M | 65 | 38 ans | |
Susan Kilsby | F | 65 | 8 ans | |
Scott Applebaum | M | 57 | 2 ans | |
Jeffrey Poulton | M | 56 | 14 ans | |
Kevin R. Tebbit | M | 76 | 12 ans | |
Christian Karst | M | 66 | 36 ans | |
Catherine Mazzacco | F | 59 |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | 2 ans |
S. Mathew | F | 68 | 7 ans | |
David R. Ginsburg | M | 71 | 8 ans | |
Namal Nawana | M | 53 | 1 ans | |
Sujata Dayal | F | 61 | 5 ans | |
Souheil Salah | M | - | 16 ans | |
William R. Mordan | M | 54 | 4 ans | |
Naseem Amin | M | 62 | 5 ans | |
Dominic Blakemore | M | 54 | 4 ans | |
Jeff Carr | M | 61 | 4 ans | |
Rosalind Rivaz | M | 68 | 3 ans | |
Grita Loebsack | F | 54 | 5 ans | |
David Altarac | M | 63 | - | |
Adam Sharkawy | M | 58 | 9 ans | |
Graham Baker | M | 56 | 3 ans | |
Ian Karp | M | - | 5 ans | |
Aditya Sehgal | M | - | 27 ans | |
Ludovic Robin | M | - | 8 ans | |
Christoph Brackmann | M | - | - | |
Sun Kim | M | 52 | 2 ans | |
Joseph Sullivan | M | - | 8 ans | |
Robin Freestone | M | 65 | 7 ans | |
James Farrell | M | 81 | - | |
Thomas Johannes W. Dittrich | M | 60 | 1 ans | |
Adrian Hennah | M | 66 | 6 ans | |
Julie Brown | F | 62 | 4 ans | |
Laura Schumacher | F | 60 | 5 ans | |
Laxman Narasimhan | M | 56 | 3 ans | |
Glenn Tilton | M | 75 | 16 ans | |
Samuel Scott | M | 79 | 13 ans | |
Edward Liddy | M | 78 | 11 ans | |
William Osborn | M | 76 | 15 ans | |
Gail D. Fosler | F | 76 | 3 ans | |
Albert P. L. Stroucken | M | 76 | 3 ans | |
Christopher Sinclair | M | 72 | 9 ans | |
Richard de Schutter | M | 83 | 13 ans | |
Steven Gillis | M | 71 | 7 ans | |
Geneviéve B. Berger | M | 69 | 2 ans | |
John Gordon Buchanan | M | 79 | 9 ans | |
Pamela Kirby | M | 70 | 12 ans | |
Erik Engstrom | M | 60 | 8 ans | |
Terrence Kearney | M | 69 | 25 ans | |
Joseph Papa | M | 68 | 10 ans | |
Brian Paul Larcombe | M | 71 | 15 ans | |
Bruno Francois Jules Angelici | M | 77 | 10 ans | |
Michael Friedman | M | 80 | 6 ans | |
Anne Minto | F | 70 | 8 ans | |
Michael Frazzette | M | 61 | 11 ans | |
Anne Quinn | F | 72 | 9 ans | |
Arjun Purkayastha | M | 45 | 10 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 49 | 49,00% |
Irlande | 24 | 24,00% |
Etats-Unis | 14 | 14,00% |
France | 7 | 7,00% |
Japon | 6 | 6,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Olivier Jean Bohuon
- Réseau Personnel